Figure 2.

Lineage circulation dynamics of SARS‐CoV‐2 during the pandemic, and vaccine effectiveness of RNA vaccines against COVID‐19. (A) Relevance of different divergent clades of SARS‐CoV‐2 during the pandemic (based on GISAID classification). (B) Circulation dynamic of different variants during the pandemic. (C) Percentage of available sequences at the GISAID database associated with the lineages described by Magalis et al., ¹ representing the low circulation of these lineages during the pandemic around the world. However, it is important to consider the huge temporal and geographical biases in sequencing and the presence of locally dominant variants that might have predominated in a single region/or country for this reason the concept of low‐circulating lineage must be taken with caution. Information about the number of sequences associated with different clades and lineages was obtained from the GISAID database. (D) Summary of the effectiveness at different clinical conditions of Moderna and Pfizer BioNTech vaccines against SARS‐COV‐2. Information was obtained from the Centers of Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html. COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.